疏肝理气汤联合肝射频消融对晚期肝癌预后的影响

Effect of Shugan Liqi decoction combined with hepatic radiofrequency ablation on the prognosis of advanced liver cancer

目的探讨疏肝理气汤联合射频消融(RFA)对晚期肝癌预后的影响。方法回顾性分析2011年2月~2014年4月我院80例接受RFA治疗的晚期肝癌患者。其中40例患者在接受RFA治疗同时,服用疏肝理气汤(中药组),其余40例患者仅接受RFA治疗(对照组)。比较两组并发症和长期生存率等指标。结果两组患者的一般资料无显著差异。未发现明显中药毒性反应。中药组肝功能衰竭发生率明显低于对照组(4/40 vs 12/40,P=0.0253)。中药组有更多患者完成RFA治疗(36/40 vs 27/40,P=0.0139)。中药组3年总生存率显著高于对照组(42.50%vs 32.50%;HR:1.8122;95%CI:1.0274~3.1964;P=0.0299)。结论疏肝理气汤能有效减少RFA引起的肝功能衰竭,提高治疗成功率,从而改善晚期肝细胞癌患者的长期生存。

Objective To investigate the effect of Shugan Liqi decoction combined with radiofrequency ablation（RFA） on the prognosis of advanced liver cancer. Methods 80 patients with advanced liver cancer who were treated with RFA from February 2011 to April 2014 were retrospectively analyzed. 40 patients were given Shugan Liqi decoction（Chinese medicine group） while receiving RFA treatment. The remaining 40 patients were only given RFA （control group）. Com- plications, long-term survival and other indicators were compared between the two groups. Results There was no sig- nificant difference in the general data between the two groups. No obvious Chinese medicine toxicity was found. The in- cidence rate of liver failure in Chinese medicine group was significantly lower than that in the control group（4/40 vs 12/ 40, P=-0.0253）. There were more patients in the Chinese medicine group who completed RFA treatment （36/40 vs 27/40, P=0.0139）. The overall 3-year survival rate in Chinese medicine group was significantly higher than that in the control group（42.50% vs 32.50%; HR： 1.8122; 95%CI： 1.0274-3.1964; P=0.0299）. Conclusion Shugan Liqi decoction can effectively reduce the liver failure caused by RFA and improve the success rate of treatment, so as to improve the long- term survival of patients with advanced hepatocellular carcinoma.